Telix Pharma Reports 19% Q3 Revenue Growth and Keeps 2026 Guidance
Telix Pharma posted 19% revenue growth in the third quarter of 2026 and reaffirmed its full-year outlook of $950 million to $970 million.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to dpa-AFX and RTTNews, Telix Pharmaceuticals' group revenue for the quarter ended September 30, 2026 rose 19% to $245 million from $206 million a year earlier. The Precision Medicine segment grew 30% to $201 million from $155 million, driven by Gozellix and Illuccix prostate cancer imaging agents.
The company reiterated its 2026 revenue guidance of $950 million to $970 million and said results are tracking toward the upper end of that range. In September it administered the first commercial doses of Pixclara for glioma imaging, and the Phase III BiPASS study on pre-biopsy prostate cancer detection completed enrollment.
On Tuesday TLX shares closed at $11.16, up 3.91%. In overnight trading the stock was up about 0.81%.
why it matters
A reaffirmed outlook alongside double-digit revenue growth matters for investors in this small biotech that sells PSMA-based diagnostic agents. The market will watch whether results reach the upper end of the guidance range by year-end.
market impact
TLX shares: reaffirmed guidance and revenue growth support interest in the stock
tags
instruments
sources
- Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance — TradingView, 21 October 2026 at 02:59 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗